A Possible Blue Print of Addressing mRNA Vaccine Efficacy

Author:

Li Boran

Abstract

As the COVID-19 pandemic progresses, more and more strategies to combat this pandemic have been proposed, and the mRNA vaccine against COVID-19 has been considered as one of the most potential therapies to terminate the pandemic. However, a few problems of it have been discovered during the whole investigation, such as instability, poor efficacy. Meanwhile, some researchers illustrated that improving the dose of mRNA vaccine to get better efficacy may induce worse adverse reactions due to the delivery of vaccine was ‘lipid nanoparticles (LNPs)’. High level of LNPs would induce cell death by their toxicity, Therefore, some new modifications of mRNA should be paid attention and applied to produce the new mRNA vaccine. It is possible to promote the development of mRNA vaccine for better stability, efficacy, and lower price. This review introduces current modifications of mRNA vaccines for improved stability and discusses some novel ideas.

Publisher

Darcy & Roy Press Co. Ltd.

Reference28 articles.

1. Real-time dynamic broadcast of the world's COVID-19 pandemic. https://news. ifeng.com/c/special/7uLj4F83Cqm. Accessed November 9, 2022.

2. Adam D. COVID's true death toll: much higher than official records. Nature. 2022 Mar; 603 (7902): 562.

3. Moderna clinical trials are published. https://trials.modernatx.com/search-results/?Search Term=COVID-19&Latitude=&Longitude=&LocationName=&conditions=&Status=&phases =&AgeRanges=&gender=&GenderDescriptions=&StudyTypes=&AttachmentTypes=&MileRadius=100&PageIndex=0&hasResults=&isHighValue=&SortField=StatusDisplay&SortOrder=asc. Accessed November 10, 2022.

4. Pfizer-BioNTech COVID-19 Vaccine Demonstrates Strong Immune Response, High Efficacy and Favorable Safety in Children 6 Months to Under 5 Years of Age Following Third Dose. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-biontech-covi d-19-vaccine-demonstrates-strong-immune. Accessed May 23, 2022.

5. Hodson R. Preparing the world for the next pandemic. Nature. 2022 Oct; 610 (7933): S33.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3